Table 1 Patient disposition . Treated... | American Society of Hematology

Table 1

Patient disposition

	Treated patients
	100 mg once daily (n = 165)		50 mg twice daily (n = 167)		140 mg once daily (n = 163)		70 mg twice daily (n = 167)		All arms (n = 662)
	No.	%	No.	%	No.	%	No.	%	No.	%
On treatment	51	31	51	31	39	24	47	28	188	28
Reason for discontinuation
Disease progression*	34	21	26	16	42	26	26	16	128	19
Study drug toxicity	34	21	40	24	42	26	48	29	164	25
Patient or investigator request	24	15	21	13	23	14	19	11	87	13
Adverse event unrelated to drug	7	4	8	5	4	2	6	4	25	4
Other†	15	9	21	13	13	8	21	13	70	11

	Treated patients
	100 mg once daily (n = 165)		50 mg twice daily (n = 167)		140 mg once daily (n = 163)		70 mg twice daily (n = 167)		All arms (n = 662)
	No.	%	No.	%	No.	%	No.	%	No.	%
On treatment	51	31	51	31	39	24	47	28	188	28
Reason for discontinuation
Disease progression*	34	21	26	16	42	26	26	16	128	19
Study drug toxicity	34	21	40	24	42	26	48	29	164	25
Patient or investigator request	24	15	21	13	23	14	19	11	87	13
Adverse event unrelated to drug	7	4	8	5	4	2	6	4	25	4
Other†	15	9	21	13	13	8	21	13	70	11

Discontinuations at up to 73.9 months are reflected. Reasons for discontinuation were reported by the investigator on the case report form.

Progression was defined as increasing white blood cell count, loss of complete hematologic response, loss of major cytogenetic response, ≥30% increase in Ph+ metaphases, or transformation to AP or BP disease.

†

Includes commercial supply, travel requirements, transplant, noncompliance, avoidance of toxicity, development of mutation, pregnancy, no response (as reported by the investigator), death unrelated to drug, other malignancy, and other reasons.

View Large

This Feature Is Available To Subscribers Only